Elranatamab-Based Triplet Effective in Transplant-Ineligible Myeloma

(MedPage Today) — TORONTO — A three-drug combination involving the B-cell maturation antigen (BCMA)-CD3 bispecific antibody elranatamab (Elrexfio) was associated with high response rates and manageable toxicity in newly diagnosed, transplant…